X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Pharma stocks in limelight 
(Tue, 28 Oct Closing) 
 
After trading firm during post noon trading session, the Indian equity markets gathered momentum and closed the day in the green. While the BSE-Sensex today closed higher by 128 points, the NSE-Nifty closed higher by 36 points. Midcaps and Smallcaps however, closed flat today. While the BSE Mid Cap index closed higher by 0.09%, the BSE Small Cap index was higher by 0.76%. Healthcare (HC) stocks were the biggest gainers today. The BSE HC Index was up by 1.4%.

As regards global markets, Asian indices closed mixed today. The rupee was trading at Rs 61.33 to the dollar at the time of writing.

Steel stocks ended the day on a weak note. Tayo Rolls and Tata Sponge were the biggest losers. India's largest steel manufacturer, Tata Steel is planning to pare its debt by selling some of its assets in Europe. It has initiated talks with a Swiss investment firm Klesch Group. It may be noted that post the Corus acquisition the company got saddled with debt to the tune of Rs 816 bn. The move is deemed as credit positive by most rating agencies as it shall help the company pare debt. Further, the domestic markets are showing signs of revival. Hence, it shall enable the company to focus in growth markets and transform itself better post a debt loaded acquisition.

Indian Pharma stocks closed on a strong note today. Sun Pharma and Ranbaxy were the biggest gainers. Pharma major Lupin announced its results today. Sales increased 18.4% YoY to Rs 31.16 bn. However, net profits increased at a faster pace of 55% YoY to Rs 6.3 bn on the back of increased sales of drug to the US and Japan. The profitability growth would have been even higher if there was no price erosion in the US market during the quarter. The stock ended the day with a marginal loss of 2.6%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Pharma stocks in limelight". Click here!

  
 

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Jul 21, 2017 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS